cannabis/neoplasms

FIELD OF THE INVENTION The present invention provides pyrazoline cannabinoid receptor antagonists/inverse agonists and pharmaceutical compositions thereof and methods of using the same for treating disease conditions including inflammatory diseases, metabolic diseases such as obesity, diabetes, and

FIELD OF THE INVENTION The present invention provides pyrazoline cannabinoid receptor antagonists/inverse agonists and pharmaceutical compositions thereof and methods of using the same for treating disease conditions including inflammatory diseases, metabolic diseases such as obesity, diabetes, and

RELATED APPLICATION This application is a national stage filing under 35 U.S.C. .sctn. 371 of International Application No. PCT/GB2015/051876, filed Jun. 26, 2015, which was published under PCT Article 21(2) in English, the entire contents of which are hereby incorporated by reference. The present

BACKGROUND Field This application relates to ameliorating radiotherapy- and chemotherapy-induced cognitive and emotional impairment and to treating cancer with cannabinoids. Background Information Chemotherapy-associated cognitive or emotional impairment, commonly known as chemo brain and chemo fog

The present invention relates to tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivatives, to pharmaceutical compositions comprising the same and to the use of these tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivatives in therapy, especially in the treatment of pain. Pain treatment is often

FIELD OF THE INVENTION The present invention, in some embodiments thereof, relates to fixed dose combination (FDC) compositions, more particularly, but not exclusively, to compositions comprising at least one cannabinoid as a plant isolate or synthetic, in essentially pure form or as a component of

FIELD OF THE INVENTION The present invention, in some embodiments thereof, relates to fixed dose combination (FDC) compositions, more particularly, but not exclusively, to compositions comprising at least one cannabinoid as a plant isolate or synthetic, in essentially pure form or as a component of

FIELD OF THE INVENTION The present invention relates to the field of cannabinoids. More specifically, the present invention describes the medical use of some quinonoid derivatives of cannabinoids, as well as some such novel compounds. BACKGROUND OF THE INVENTION All publications mentioned throughout

RELATED APPLICATIONS This application is a national stage filing under 35 U.S.C. .sctn.371 of international application PCT/GB2009/050621, filed Jun. 4, 2009, which was published under PCT Article 21(2) in English. The present invention relates to the use of a combination of cannabinoids in the

FIELD The present disclosure relates to the field of cannabinoid receptors and, in particular, to methods of regulating cannabinoid (CB) receptor activity-related disorders and diseases, such as activating CB receptors, including treating a disorder or disease, such as a glioblastoma, hepatocellular

FIELD The present disclosure relates to the field of cannabinoid receptors and, in particular, to methods of regulating cannabinoid (CB) receptor activity-related disorders and diseases, such as activating CB receptors, including treating a disorder or disease, such as a glioblastoma, hepatocellular

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a National Stage Application under 35 U.S.C. .sctn.371 of International Application No. PCT/US2010/002360, filed Aug. 27, 2010, which claims priority under 35 U.S.C. .sctn.119(e) to U.S. Provisional Application Nos. 61/275,506, filed Aug.

FIELD OF THE INVENTION The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB.sub.2 receptor. The present invention further relates to certain compounds of Formula Ia and pharmaceutical compositions

FIELD OF THE INVENTION The present invention provides pyrazoline cannabinoid receptor antagonists/inverse agonists and pharmaceutical compositions thereof and methods of using the same for treating conditions including obesity, diabetes, hepatic disorders, cardiometabolic disorders, and/or

FIELD OF THE INVENTION The present invention provides pyrazoline cannabinoid receptor antagonists/inverse agonists and pharmaceutical compositions thereof and methods of using the same for treating conditions including obesity, diabetes, hepatic disorders, cardiometabolic disorders, and/or